Sheena Jonathan, a co-founder of Natera, Inc. (NASDAQ:NTRA), executed a sale of 3,150 shares of the company’s common stock on June 15, 2026. The total value of the transaction was approximately $665,087, with the shares changing hands at prices ranging from $210.2921 to $213.5383 per share. These sales were conducted under a Rule 10b5-1 trading plan that Ms. Jonathan adopted on December 12, 2025.
Following the transaction, Ms. Jonathan directly holds 249,352 shares of Natera common stock. In addition to her direct holdings, she maintains indirect interests through two separate vehicles: the Caraluna 1 Trust and the Caraluna 2 Trust. Each trust holds 19,532 shares on her behalf. Ms. Jonathan has formally disclaimed beneficial ownership over these indirectly held securities, which are maintained for the benefit of the trusts’ beneficiaries.
The stock has demonstrated recent momentum, climbing to $226.44, which represents a gain of over 6% from the prices at which Ms. Jonathan sold her shares. Despite this recent appreciation and a strong 32% return over the past year, InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value, placing it among the most overvalued stocks in its sector.
Key Points
- Insider Sales Under Pre-Arranged Plan: Ms. Jonathan's sale of 3,150 shares was executed under a Rule 10b5-1 trading plan adopted in December 2025, indicating a pre-arranged schedule rather than a reactive market decision.
- Continued Significant Ownership: Despite the sale, Ms. Jonathan retains a substantial direct stake in Natera, holding 249,352 shares, while maintaining additional indirect holdings through the Caraluna 1 and Caraluna 2 trusts.
- Analyst Initiations and Board Expansion: Natera has seen recent analyst coverage initiations and corporate governance changes, including the appointment of oncology experts Thomas Lynch and Eric Rubin to its board, and a 3.2 million share increase to its 2015 Equity Incentive Plan following shareholder approval.
Risks and Uncertainties
- Valuation Concerns: InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value, placing it among the most overvalued stocks in its sector, which may impact future price movements.
- Operating Leverage Dependencies: Goldman Sachs highlighted the need to monitor additional operating leverage benefits as the company scales, indicating potential challenges in maintaining growth efficiency.
- Market Sentiment Variability: Analyst ratings vary, with RBC Capital and Wolfe Research initiating with "Outperform" ratings, while Goldman Sachs began coverage with a "Neutral" rating, reflecting mixed views on the company's near-term prospects.
Additional corporate developments include shareholder approval of an amendment to Natera’s 2015 Equity Incentive Plan, which increases the shares reserved for issuance by 3.2 million. This amendment allows company officers and directors to receive awards under the revised plan. The company also appointed two oncology experts, Thomas Lynch and Eric Rubin, to its board of directors, enhancing its leadership with significant experience in cancer research and treatment.
On the analyst front, RBC Capital initiated coverage of Natera with an "Outperform" rating, citing growth opportunities in minimal residual disease monitoring as a key factor. Wolfe Research also initiated coverage with an "Outperform" rating and set a price target of $260, based on a long-term growth model. Meanwhile, Goldman Sachs began coverage with a "Neutral" rating and a $245 price target, acknowledging Natera’s leadership in the minimal residual disease market but watching for additional operating leverage benefits as the company scales.
These developments reflect a mix of optimism and cautious observation from analysts regarding Natera’s future prospects. The stock closed at $226.44, representing a gain of $6.33 or 2.88% on the day, with after-hours trading showing a further increase to $232.84, up $6.40 or 2.83%.